Heidelberg Pharma Presents Proprietary ATAC Technology Platform at Two Scientific Conferences

DGAP-News: Heidelberg Pharma AG / Key word(s): Conference

09.04.2018 / 09:01

The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

Heidelberg Pharma Presents Proprietary ATAC Technology Platform at Two Scientific Conferences

Ladenburg, Germany, 9 April 2018 – Heidelberg Pharma AG (FWB: WL6) today announced that they will present their proprietary ATAC technology platform at two upcoming scientific conferences.

6th Annual Antibodies & Antibody Drug Conjugates Conference
Date: 9 – 10 April 2018
Venue: Copthorne Tara Hotel London Kensington, London, UK

Professor Andreas Pahl will present the following speech on Monday, 9 April 2018 at 11.40 a.m. BST:

Antibody Targeted Amanitin Conjugates (ATACs) – Expanding the ADC landscape with a new payload targeting RNA Polymerase II

AACR Annual Meeting 2018
Date: 14 – 18 April 2018
Venue: McCormick Place North/South, Chicago, USA

Heidelberg Pharma will announce scientific data in the course of two poster presentations. One poster shows structure-effect relationships for synthetic variants of Amanitin-linker molecules which are particularly suitable for the treatment of solid tumors. The other poster shows preclinical data of an ATAC which is directed to PSMA. This protein is relevant inter alia for prostate cancer.

Details of the presentations:

Structure-Activity relationship of Linker-Amanitin variants and optimization of Linker-Amanitin derivatives for the treatment of solid tumors
Abstract number: 735, Section 35
Speaker: Dr. Michael Kulke
Date: Sunday, 15 April 2018, 1.00 p.m. – 5.00 p.m. CDT

Preclinical evaluation of an anti-PSMA antibody-targeted Amanitin conjugate
Abstract number: 740, Section 35
Speaker: Dr. Christian Breunig
Date: Sunday, 15April 2018, 1.00 p.m. – 5.00 p.m. CDT

The abstracts of the presentations are available on the website of AACR: http://www.abstractsonline.com/pp8/#!/4562/presentation/2997 and http://www.abstractsonline.com/pp8/#!/4562/presentation/3002.

About Heidelberg Pharma’s proprietary ATAC technology
Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.

About Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates. The proprietary lead candidate is HDP-101, a BCMA ATAC for multiple myeloma.

The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON(R) and REDECTANE(R), while RENCAREX(R) is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.

Contact
Heidelberg Pharma AG
Corporate Communications
Sylvia Wimmer
Tel.: +49 89 41 31 38-29
E-Mail: investors[at]hdpharma.com
Schriesheimer Str. 101, 68526 Ladenburg
IR/PR support
MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 210 228-40
Mobil: +49 160 9360 3022
E-Mail: katja.arnold[at]mc-services.eu
 

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.


09.04.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Heidelberg Pharma AG
Schriesheimer Str. 101
68526 Ladenburg
Germany
Phone: +49 (0)89 41 31 38 – 0
Fax: +49 (0)89 41 31 38 – 99
E-mail: investors@hdpharma.com
Internet: www.heidelberg-pharma.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this